A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms
NCT ID: NCT03511768
Last Updated: 2018-04-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
65 participants
INTERVENTIONAL
2018-01-02
2020-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
18F-AlF-NOTA-octreotide PET/CT
One injection of the radioligand 18F-AlF-NOTA-octreotide
18F-AlF-NOTA-octreotide
One injection of 18F-AlF-NOTA-octreotide
PET/CT
Following injection of 18F-AlF-NOTA-octreotide the participants will be subjected to whole body PET/CT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
18F-AlF-NOTA-octreotide
One injection of 18F-AlF-NOTA-octreotide
PET/CT
Following injection of 18F-AlF-NOTA-octreotide the participants will be subjected to whole body PET/CT
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Signed informed consent.
Exclusion Criteria
2. Pregnant or breast-feeding
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xiangya Hospital of Central South University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tingting Long, MD,Phd
Role: PRINCIPAL_INVESTIGATOR
Department of PET Center,Xiangya Hospital, Central South University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of PET Center,Xiangya Hospital,Central South University
Changsha, Hunan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Tingting Long, MD,Phd
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Laverman P, McBride WJ, Sharkey RM, Eek A, Joosten L, Oyen WJ, Goldenberg DM, Boerman OC. A novel facile method of labeling octreotide with (18)F-fluorine. J Nucl Med. 2010 Mar;51(3):454-61. doi: 10.2967/jnumed.109.066902. Epub 2010 Feb 11.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
201801001
Identifier Type: -
Identifier Source: org_study_id